Tower Research Capital (TRC)’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.76K | Sell |
4,101
-2,908
| -41% | -$8.01K | ﹤0.01% | 4012 |
|
|
2026
Q1 | $19.3K | Buy |
7,009
+843
| +14% | +$2.62K | ﹤0.01% | 3505 |
|
|
2025
Q4 | $19.4K | Buy |
6,166
+2,860
| +87% | +$9.02K | ﹤0.01% | 3117 |
|
|
2025
Q3 | $9.55K | Buy |
3,306
+231
| +8% | +$522 | ﹤0.01% | 4022 |
|
|
2025
Q2 | $6.24K | Sell |
3,075
-3,789
| -55% | -$6.59K | ﹤0.01% | 4118 |
|
|
2025
Q1 | $12.8K | Sell |
6,864
-49
| -0.7% | -$123 | ﹤0.01% | 3420 |
|
|
2024
Q4 | $18.7K | Buy |
6,913
+4,028
| +140% | +$12.6K | ﹤0.01% | 3243 |
|
|
2024
Q3 | $10.9K | Sell |
2,885
-189
| -6% | -$660 | ﹤0.01% | 3712 |
|
|
2024
Q2 | $12.3K | Sell |
3,074
-2,756
| -47% | -$9.12K | ﹤0.01% | 4043 |
|
|
2024
Q1 | $17.3K | Buy |
5,830
+5,052
| +649% | +$18.1K | ﹤0.01% | 3129 |
|
|
2023
Q4 | $3.89K | Sell |
778
-18,860
| -96% | -$60.6K | ﹤0.01% | 5029 |
|
|
2023
Q3 | $56K | Buy |
19,638
+19,248
| +4,935% | +$58.6K | ﹤0.01% | 2448 |
|
|
2023
Q2 | $1.15K | Sell |
390
-163
| -29% | -$356 | ﹤0.01% | 5451 |
|
|
2023
Q1 | $1K | Buy |
+553
| New | +$1.28K | ﹤0.01% | 5487 |
|
|
2022
Q4 | – | Sell |
-3,334
| Closed | -$11K | – | 5835 |
|
|
2022
Q3 | $11K | Buy |
3,334
+922
| +38% | +$2.9K | ﹤0.01% | 4415 |
|
|
2022
Q2 | $9K | Sell |
2,412
-5,245
| -68% | -$17.9K | ﹤0.01% | 4531 |
|
|
2022
Q1 | $30K | Buy |
7,657
+2,166
| +39% | +$9.38K | ﹤0.01% | 3132 |
|
|
2021
Q4 | $28K | Sell |
5,491
-5,700
| -51% | -$33.1K | ﹤0.01% | 3288 |
|
|
2021
Q3 | $75K | Buy |
11,191
+8,972
| +404% | +$64.2K | ﹤0.01% | 2633 |
|
|
2021
Q2 | $18K | Sell |
2,219
-2,769
| -56% | -$19.1K | ﹤0.01% | 3975 |
|
|
2021
Q1 | $38K | Sell |
4,988
-1,637
| -25% | -$11.7K | ﹤0.01% | 3348 |
|
|
2020
Q4 | $34K | Sell |
6,625
-163
| -2% | -$832 | ﹤0.01% | 3465 |
|
|
2020
Q3 | $33K | Buy |
6,788
+14
| +0.2% | +$100 | ﹤0.01% | 3691 |
|
|
2020
Q2 | $45K | Buy |
6,774
+6,762
| +56,350% | +$49.1K | ﹤0.01% | 3127 |
|
|
2020
Q1 | $0 | Sell |
12
-8,728
| -100% | -$68.2K | ﹤0.01% | 2957 |
|
|
2019
Q4 | $75K | Sell |
8,740
-3,714
| -30% | -$24.8K | 0.01% | 1109 |
|
|
2019
Q3 | $62K | Buy |
+12,454
| New | +$66.7K | ﹤0.01% | 1637 |
|
|
2019
Q2 | – | Sell |
-8,164
| Closed | -$41K | – | 3588 |
|
|
2019
Q1 | $41K | Buy |
+8,164
| New | +$51.9K | ﹤0.01% | 1862 |
|
|
2018
Q4 | – | Sell |
-4,018
| Closed | -$32K | – | 3772 |
|
|
2018
Q3 | $32K | Buy |
+4,018
| New | +$40.4K | ﹤0.01% | 2027 |
|
|
2018
Q1 | – | Sell |
-549
| Closed | -$7K | – | 3180 |
|
|
2017
Q4 | $7K | Buy |
+549
| New | +$6.46K | ﹤0.01% | 2718 |
|
|
2017
Q3 | – | Sell |
-3,045
| Closed | -$27K | – | 3735 |
|
|
2017
Q2 | $27K | Buy |
+3,045
| New | +$28.2K | ﹤0.01% | 1052 |
|
Other funds holding ACIU
Tower Research Capital (TRC)'s ACIU Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its AC Immune (ACIU) stake by 41% in Q2 2026, selling an estimated $8.01K and leaving 4,101 shares worth $9.76K. The position accounts for ﹤0.01% of the portfolio, ranked #4012.
Tower Research Capital (TRC) first reported a position in ACIU in Q2 2017 and has held it in 31 quarters since. The position peaked at $75K in Q3 2021. 40 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.
- Tower Research Capital (TRC) held 4,101 shares of AC Immune worth $9.76K as of Q2 2026.
- Tower Research Capital (TRC) sold 2,908 AC Immune shares in Q2 2026, an estimated $8.01K.
- AC Immune made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4012 holding.
- Tower Research Capital (TRC) first reported a position in AC Immune in Q2 2017 and has held it in 31 quarters since.
- Tower Research Capital (TRC)'s AC Immune position peaked at $75K in Q3 2021.
- 40 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.